## AMENDMENTS TO THE CLAIMS

Docket No.: 62661(52171)

Claims 1-18 (Cancelled).

Claim 19. (Currently Amended) A compound of the following general formula:

$$R^{1} \xrightarrow[R^{2}]{R^{4}} \xrightarrow[R^{5}]{0} \xrightarrow[R^{6}]{R^{7}} \xrightarrow[R^{8}]{0} \xrightarrow[R^{10}]{0} \xrightarrow[R^{12}]{0}$$

wherein:

A represents an optionally substituted 5- or 6-membered heteroaryl ring

X is O, S or a group of Formula NR<sup>13</sup> or CR<sup>14</sup>R<sup>15</sup>;

Y is O, S or a group of Formula NR<sup>16</sup> and

R<sup>1</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup> and R<sup>16</sup> are independently of each other H, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aralkyl or heteroaralkyl,

 $\mathsf{R}^2$  and  $\mathsf{R}^3$  together constitute a group of Formula (CH2)n wherein n is 2, 3, 4 or 5; and

R<sup>8</sup> is hydrogen or alkyl;

R<sup>12</sup> is H, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl, heteroaralkyl or NR<sup>18</sup>R<sup>19</sup>;

## R<sup>18</sup> is H or methyl; and

## R<sup>19</sup> is aralkyl or heteroaralkyl

or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof $_{\tau_2}$ 

wherein compounds of Formula (I) are excluded,

wherein R' is H, alkyl, alkenyl, aryl, or heteroaryl, and R" is H, OH, alkyl, aryl or heteroaryl.

Claim 20. (Previously Presented) A compound of claim 19, wherein A has the following structure:

Claim 21. (Previously Presented) A compound of claim 19 wherein X is a  $CH_2$  group.

Claim 22. (Previously Presented) A compound of claim 19 wherein Y is O.

Claim 23. (Previously Presented) A compound of claim 19 wherein  $R^1$  is  $C_1$ -  $C_4$  alkyl.

Claim 24. (Canceled)

Claim 25. (Previously Presented) A compound of claim 19 wherein R<sup>4</sup> is H or methyl.

Claim 26. (Previously Presented) A compound of claim 19 wherein R<sup>5</sup> is H.

Claim 27. (Previously Presented) A compound of claim 19 wherein  $R^6$  is  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_6$  cycloalkyl or  $C_4$ - $C_7$  alkylcycloalkyl.

Claim 28. (Previously Presented) A compound of claim 19 wherein  $R^7$  is H or methyl.

Claim 29. (Canceled)

Claim 30. (Previously Presented) A compound of claim 19 wherein  $R^9$  is  $C_{1}$ -  $C_{6}$  alkyl.

Claim 31. (Previously Presented) A compound of claim 19 wherein R<sup>10</sup> is H or methyl.

Claim 32. (Previously Presented) A compound of claim 19 wherein  $R^{11}$  is H or a group of Formula (C=O)-(C<sub>1-4</sub>)alkyl.

Claim 33. (Previously Presented) A compound of claim 19 wherein R<sup>12</sup> is a group of Formula NR<sup>18</sup>R<sup>19</sup>, wherein R<sup>18</sup> is H or methyl and R<sup>19</sup> is aralkyl or heteroaralkyl.

Claim 34. (Previously Presented) A pharmaceutical composition comprising a compound of claim 19 and optionally one or more carriers and/or adjuvants.

Claim 35. (Canceled)

Claim 36. (Canceled)

Claim 37. (Withdrawn, Currently Amended) A method for treating a patient suffering from cancer colon cancer, breast cancer, ovarian cancer, epidermoid cancer or prostate cancer, comprising administering to the patient one or more compounds of claim 19.

Claim 38. (Withdrawn, Currently Amended) The method of claim 37 wherein the patient is identified as suffering from cancer colon cancer, breast cancer, ovarian cancer, epidermoid cancer or prostate cancer, and the one or more compounds are administered to the identified patient.

Claim 39. (New) The compound according to Claim 19 wherein R<sup>12</sup> is NR<sup>18</sup>R<sup>19</sup>;

R<sup>18</sup> is H or methyl;

R<sup>19</sup> has the formula:

wherein:

R<sup>21</sup> is –OH, –NH<sub>2</sub>, alkyloxy, alkylamino or dialkylamino;

R<sup>22</sup> is halogen, -OH, -NO<sub>2</sub>, -NH<sub>2</sub>, alkyloxy, alkylamino or dialkylamino; and

Application No. 10/520,793 7
Amendment dated November 17, 2009
Response to Office Action dated July 17, 2009

Docket No.: 62661(52171)

p is 0, 1, 2 or 3.